BIA 51058

Drug Profile

BIA 51058

Alternative Names: BIA 5-1058

Latest Information Update: 14 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bial
  • Developer BIAL
  • Class Antihypertensives; Heart failure therapies
  • Mechanism of Action Dopamine beta hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure; Pulmonary arterial hypertension

Most Recent Events

  • 14 Mar 2016 Phase I development is ongoing in the Netherlands
  • 01 Mar 2011 Phase-I clinical trials in Heart failure in Netherlands (PO)
  • 01 Mar 2011 Phase-I clinical trials in Pulmonary arterial hypertension in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top